Mylan 3Q: Abbott deal will still result in successful 'inversion'
This article was originally published in Scrip
Executive Summary
Mylan has upped its guidance on strong third-quarter results and CEO Heather Bresch also used the firm's financial reporting to confirm once again that the company's acquisition of Abbott's generics unit is still on.